Company Description
Bambusa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops long-acting bispecific antibodies for the treatment of immunological and inflammatory disorders.
The company develops BBT001 for Type 2 inflammatory dermatological conditions, including atopic dermatitis, chronic spontaneous urticaria, and prurigo nodularis.
It also develops BBT002, a long-acting bispecific antibody for respiratory and other Type 2 inflammatory diseases.
Additionally, the company develops BBT003, a long-acting bispecific antibody for inflammatory bowel disease, including ulcerative colitis and Crohn's disease.
The company also develops BBT004 for depletion of pathogenic B cells and antibody-producing plasma cells in autoantibody-driven autoimmune diseases.
The company operates in the United States, Australia, New Zealand, China, Europe, and internationally.
Bambusa Therapeutics, Inc. was incorporated in 2024 and is based in Boston, Massachusetts.
| Country | United States |
| Founded | 2024 |
| IPO Date | Oct 30, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Shanshan Xu |
Contact Details
Address: 22 Boston Wharf Road, Floor 7 Boston, Massachusetts 02210 United States | |
| Phone | (617) 848-6188 |
| Website | bambusatx.com |
Stock Details
| Ticker Symbol | BBTX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 2044950 |
| CUSIP Number | 058937103 |
| ISIN Number | US0589371030 |
| Employer ID | 99-2083913 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Shanshan Xu, M.D., Ph.D., M.B.A. | Co-Founder, Chief Executive Officer, President, and Chairperson |
| Jonathan I. Lieber, M.B.A. | Chief Financial Officer |
| Thang Ho, Ph.D. | Co-Founder and Chief Development Officer |
| Crystal MacKay | Chief Operating Officer |
| Derek DiRocco, Ph.D. | Director |
| Christian Foerster, M.Sc. | Director |
| Helmut Jeggle, M.B.A. | Co-Founder and Director |
| Howard Liang, Ph.D., M.B.A. | Lead Independent Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 6, 2026 | SCHEDULE 13D | Filing |
| Nov 5, 2026 | SCHEDULE 13G | Filing |
| Nov 3, 2026 | 8-K | Current Report |
| Oct 30, 2026 | 424B4 | Prospectus |
| Oct 30, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Oct 29, 2026 | EFFECT | Notice of Effectiveness |
| Oct 29, 2026 | S-1MEF | Registration adding securities to prior Form S-1 registration |
| Oct 29, 2026 | CERT | Certification by an exchange approving securities for listing |
| Oct 27, 2026 | 8-A12B | Registration of securities |
| Oct 26, 2026 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |